US launch augers well for Lupin

Updated - June 13, 2014 at 09:42 PM.

14blLupinCol.eps

Shares of Lupin are likely to remain active next week, as its subsidiary Lupin Pharmaceuticals Inc has launched ciprofloxacin oral suspension (5g per 100ml and 10g per 100ml), in the US. The oral suspension is used to treat infections caused by susceptible isolates of designated micro-organisms in various conditions and patient populations. Cipro oral suspension had annual US sales of $8.6 million. Lupin has 180 days of marketing exclusivity in the US.

Published on June 13, 2014 16:12